CytoMed Therapeutics Pte. Ltd. (GDTC)

CytoMed Therapeutics Pte. will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -1.47M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About GDTC

CytoMed Therapeutics is a pre-clinical biopharmaceutical company focused on harnessing our licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. We have established two novel patient blood cell-independent platform technologies to manufacture “off-the-shelf” cell-based cancer immunotherapies, meaning the manufacturing of the stated cell therapies in quantities, which utilizes either donor blood cells or iPSCs as starting materials, but not the limited patient’s own blood cells and... [Read more]

Industry Health Care
Founded 2018
CEO CHOO Chee Kong
Employees 24
Stock Exchange NASDAQ
Ticker Symbol GDTC
Full Company Profile

Financial Performance

Financial numbers in SGD Financial Statements


CytoMed Therapeutics IPO Registration Document (F-1)

CytoMed Therapeutics has filed to go public with an IPO on the NASDAQ.

1 week ago - SEC